Susquehanna Fundamental Investments LLC Invests $2.61 Million in Guardant Health, Inc. (NASDAQ:GH)

Susquehanna Fundamental Investments LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 85,267 shares of the company’s stock, valued at approximately $2,605,000.

A number of other large investors have also recently bought and sold shares of GH. Norges Bank acquired a new position in shares of Guardant Health during the 4th quarter worth about $36,438,000. Lord Abbett & CO. LLC acquired a new position in shares of Guardant Health during the third quarter worth approximately $15,624,000. Vanguard Group Inc. boosted its position in shares of Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after acquiring an additional 350,606 shares during the period. Eversept Partners LP acquired a new stake in shares of Guardant Health in the fourth quarter worth $8,433,000. Finally, Blue Water Life Science Advisors LP raised its stake in Guardant Health by 53.9% during the 4th quarter. Blue Water Life Science Advisors LP now owns 694,047 shares of the company’s stock valued at $21,203,000 after purchasing an additional 243,000 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Performance

Shares of GH opened at $49.53 on Wednesday. The company has a market cap of $6.11 billion, a price-to-earnings ratio of -13.91 and a beta of 1.45. The stock has a fifty day moving average price of $43.40 and a two-hundred day moving average price of $37.69. Guardant Health, Inc. has a 52-week low of $17.55 and a 52-week high of $50.89.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. As a group, research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GH. Piper Sandler raised their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a report on Monday, February 24th. The Goldman Sachs Group lifted their price objective on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Mizuho initiated coverage on Guardant Health in a research note on Thursday, April 10th. They issued an “outperform” rating and a $55.00 target price for the company. Finally, Stephens reaffirmed an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Guardant Health presently has an average rating of “Buy” and an average target price of $49.00.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.